KR20190065581A - Pharmaceutical composition for preventing and treating kidney disease use extract containing mealworm and hippocampus abdominalis, health functional food composition - Google Patents

Pharmaceutical composition for preventing and treating kidney disease use extract containing mealworm and hippocampus abdominalis, health functional food composition Download PDF

Info

Publication number
KR20190065581A
KR20190065581A KR1020170164875A KR20170164875A KR20190065581A KR 20190065581 A KR20190065581 A KR 20190065581A KR 1020170164875 A KR1020170164875 A KR 1020170164875A KR 20170164875 A KR20170164875 A KR 20170164875A KR 20190065581 A KR20190065581 A KR 20190065581A
Authority
KR
South Korea
Prior art keywords
hippocampus
vancomycin
mealworm
preventing
functional food
Prior art date
Application number
KR1020170164875A
Other languages
Korean (ko)
Other versions
KR102445881B1 (en
Inventor
이민호
신재호
이미경
석푸름
Original Assignee
을지생명과학 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 을지생명과학 주식회사 filed Critical 을지생명과학 주식회사
Priority to KR1020170164875A priority Critical patent/KR102445881B1/en
Publication of KR20190065581A publication Critical patent/KR20190065581A/en
Application granted granted Critical
Publication of KR102445881B1 publication Critical patent/KR102445881B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/63Arthropods
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/20Natural extracts
    • A23V2250/204Animal extracts
    • A23V2250/2042Marine animal, fish extracts

Abstract

The present invention confirms that an extract of mealworm and Hippocampus coronatus enhances kidney function by reducing a blood urea nitrogen (bun) content, a blood creatinine (cr) content, a number of necrotic tubular cells and defending oxidative stress. Therefore, the present invention can be usefully used as a pharmaceutical composition having a use for preventing and treating kidney disease and a health functional food for improving kidney function.

Description

고소애와 해마 추출물을 함유하는 신장 질환 예방 및 치료용 약학 조성물과 건강기능식품 조성물 {Pharmaceutical composition for preventing and treating kidney disease use extract containing mealworm and hippocampus abdominalis, health functional food composition} Pharmaceutical composition for preventing and treating kidney disease use extract containing mealworm and hippocampus abdominalis, health functional food composition}

본 발명은 고소애와 해마 혼합 추출물을 유효 성분으로 함유하는 반코마이신에 의한 신장 독성의 예방 또는 치료용 약학적 조성물 또는 개선용 건강기능식품 조성물에 관한 것이다. The present invention relates to a pharmaceutical composition for preventing or treating renal toxicity caused by vancomycin or a health functional food composition for improving it, containing a mixed extract of heightened aphids and hippocampus as an active ingredient.

육류와 같은 단백질에 대한 소비가 증가함에 따라 이러한 수요를 만족시킬 수 있는 새로운 동물성 단백질 공급처에 대한 관심이 증가하고 있다. 지구상에 존재하는 1천만종 이상의 곤충 중 약 1,500종에 달하는 식용 곤충은 인간과 동물이 먹을 수 있는 단백질 공급원으로 제안되어왔다. ‘고소한 애벌레’라는 뜻의 고소애는 거저리과에 속하는 갈색거저리의 애벌레로 흔히 밀웜(mealworm)이라고도 부르며 주로 반려동물의 먹이와 식용 곤충으로 많이 사용된다. 고소애는 단백질 56.58%, 지방 28.20%로 식물성 단백질에 비해 단백질과 불포화지방산 함량이 높아 심혈관 질환 예방에 탁월한 효과가 있으며 병원식으로도 공급되고 있다. 또한 amino acid (leucine 4.5%, valine 3%, isoleucine 2.5%)이 많은 고영양식품이며 에너지 기여도가 379 ~ 573 kcal / 100g 으로 성인 기준 필요한 일일 에너지의 약 1/4을 충족시킨다. 이러한 고소애는 질량 대비 단백질의 비율도 높고, 무엇보다 키우는데 드는 에너지 대비 회수 가능한 저장 에너지 비율도 압도적이다. 게다가 강력한 박테리아를 가지고 있다. 고소애의 뱃속에서 발견된 강력한 박테리아는 종이는 물론 스티로폼을 분해해 유기물로 전환하여 일반 사료를 준 개체와 똑같이 자랐다는 연구결과가 보고됐다. 이미 중국과 남미, 동남아에서 식용으로 이용되고 있으며 식량 농업기구와 같은 국제 기구에서는 기아 퇴치와 식량 안보를 위한 방법으로 곤충 소비를 장려하는 정책을 발표해왔다. 따라서 고소애는 높은 생식능력과 고효율의 유기물 전환, 저렴한 사육 비용으로 인류의 생활 환경이 인구 폭증, 생태계 파괴 등으로 현재와 같은 육류 생산 체계를 유지할 수 없는 상황이 올 경우 새로운 대체 식량으로 주목받게 될 가능성이 높다.As consumption of proteins such as meat increases, interest in new sources of animal protein that can satisfy this demand is increasing. Of the more than 10 million insect species on Earth, about 1,500 edible insect species have been proposed as dietary protein sources for humans and animals. Kosaeae, which means “savory caterpillar,” is a larva of the brown mealworm belonging to the Mealworm family. Kosoae contains 56.58% protein and 28.20% fat. It has a high protein and unsaturated fatty acid content compared to vegetable protein, so it has an excellent effect on preventing cardiovascular diseases and is also supplied as hospital food. It is also a highly nutritious food with a lot of amino acids (leucine 4.5%, valine 3%, isoleucine 2.5%), and its energy contribution is 379 ~ 573 kcal / 100g, satisfying about 1/4 of the daily energy required by adults. These high love birds have a high ratio of protein to mass, and above all, the ratio of recoverable stored energy to energy required to grow is overwhelming. Besides, it has powerful bacteria. A research result was reported that the strong bacteria found in the stomach of Ko-Ae-ae decomposes paper and Styrofoam and converts them into organic matter, growing just like the animals given normal feed. They are already used for food in China, South America and Southeast Asia, and international organizations such as the Food and Agriculture Organization have announced policies to encourage insect consumption as a way to combat hunger and ensure food security. Therefore, high fertility, high-efficiency organic matter conversion, and low breeding cost will attract attention as a new alternative food when the current meat production system cannot be maintained due to population explosion and ecosystem destruction. Most likely.

세계자연보전연맹의 적색목록(Red List) 및 멸종위기에 처한 야생동식물의 국제거래에 관한 협약(CITES)에 따라 세계적으로 보호받는 종인 해마는 실고기과에 속하는 해마속(Hippocampus)어류의 총칭이다. “Hippocampus”는 고대그리스어로 “말”을 뜻하는 “Hippo”와 “바다 괴물”을 뜻하는 “Kampos”에서 유래되었다. 일부일처 습성을 지닌 해마는 수컷이 출산하는 것으로 알려져 있으며 암컷이 수컷의 배에 있는 보육낭(brood pouch) 속에 알을 낳으면, 수컷은 수정란을 돌보고 부화시킨다. 아울러 태어난 새끼가 독립할 수 있을 때까지 자신의 보육낭에서 키워 약 0.7㎝ 정도까지 성장한 30∼70개체의 치어를 출산한다. 몸빛은 갈색이며 몸을 보호 해주는 작은 골판으로 연결된 몸의 길이는 6~10cm 정도이고 식생도 가늘고 긴 주둥이를 이용하여 작은 동물들을 빨아들여 먹는다. 해마는 오염되지 않은 아열대 바다 얕은 수심에 주로 서식하는데 우리나라 연안에서는 수온과 오염 되고 있는 연안 환경 탓에 해마를 찾기 어렵다. 그러나 최근, 제주도에서 국내 유일의 해마 대량 양식장이 조성되어 해마를 이용한 약용과 건강 보조식품 생산은 물론 중국 수출 등 양식어업인의 새로운 양식품종으로 기대를 모으고 있다. 또한, 2012년 세계에서 처음으로 발견됐던 전남 완도군 일대 ‘소안해마’는 신종 후보종으로, 인공증식으로 70%에 가까운 생존율을 보여 인공증식이 성공하였으며 2018년도에 약 천마리 이상이 생산되면 자연적응을 거쳐 소안도 거머리말 군락지내에 방사할 계획이다. 이로인해 보호종인 국내 해마 개체 수를 안정적으로 유지할 수 있을 것이다.The seahorse, a globally protected species according to the International Union for Conservation of Nature's Red List and the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES), is a collective term for fish belonging to the genus Hippocampus. “Hippocampus” is derived from the ancient Greek words “Hippo” meaning “horse” and “Kampos” meaning “sea monster”. In monogamous seahorses, males are known to give birth, and the female lays eggs in a brood pouch on the male's abdomen, which the male tends to and incubates. In addition, until the offspring can become independent, they raise them in their own nursery bag and give birth to 30 to 70 fry that have grown to about 0.7 cm. The color of the body is brown, and the length of the body connected by the small corrugated plate that protects the body is about 6 ~ 10cm. Seahorses mainly live in shallow waters of uncontaminated subtropical seas, but it is difficult to find seahorses in coastal areas of Korea due to water temperature and polluted coastal environment. However, recently, the only large-scale seahorse farm in Korea has been established in Jeju Island, and it is expected to be a new breed of fishermen for export to China as well as medicinal and health supplement production using seahorses. In addition, the 'Soan seahorse', which was discovered for the first time in the world in 2012 in Wando-gun, Jeollanam-do, is a new candidate species, with a survival rate close to 70% through artificial breeding, so artificial breeding was successful. Afterwards, it is planned to be released in the leech horse colony in Soan Island. As a result, it will be possible to stably maintain the domestic seahorse population, which is a protected species.

현재 까지 가장 많이 이용 되고 있는 약제로서의 해마의 효용에 대하여 문헌상에 보고된 내용을 보면 내장을 제외한 모든 부분을 약용으로 사용되고 있으며 주요성분은 arginine, aspartic acid, alanine, glycine, proline, glutamic acid 등 20가지 amino acid을 함유하고 있으며 약용가치가 높은 타우린을 비롯한 칼슘, 마그네슘, 칼륨, 나트륨, 철, 아연, 망간, 구리, 크롬, 아연 등의 풍부한 무기원소를 함유하고 있다. 약의 특성은 단맛과 짠맛이 나며 약의 성질은 따뜻하고 간과 신장으로 귀경하기 때문에 보신장양(補腎壯陽), 조기활혈(調氣活血), 산결소종(散結消腫)하는 요약으로 널리 알려져 있다.Looking at the information reported in the literature on the efficacy of the hippocampus as the most used drug so far, all parts except the intestines are used for medicinal purposes, and the main ingredients are arginine, aspartic acid, alanine, glycine, proline, and glutamic acid. It contains amino acid and contains abundant inorganic elements such as calcium, magnesium, potassium, sodium, iron, zinc, manganese, copper, chromium, and zinc, including taurine with high medicinal value. The characteristics of the medicine are sweet and salty, and the nature of the medicine is warm and returns to the liver and kidneys, so it is widely known as a summary of nourishing the kidneys (補腎壯陽), early blood (調气活血), and sangyeolsojong (散結消腫).

Vancomycin은 Streptomyces orientalis에서 분리된 항생물질로서, glycopeptide 항생제로 50 년 이상 동안 methicillin-resistant staphylococcus aureus (MRSA) 감염을 치료하는 데 사용되어 왔다. 살균작용은 신속하게 나타나며 세균의 내성발현은 현저하지 않다. 소화관에서 흡수되지 않기 때문에 정맥 내에 투여되며 작용의 지속은 길다. 부작용으로서는 피부발진, 발열시의 과민성반응이 있으나 주요한 것은 청신경장애와 신장장애이다. 보고 된 vancomycin에 의한 신 독성의 발생률은 5-25 %이다. vancomycin에 의한 신 독성의 정확한 기전은 알려지지 않았지만, 산화 스트레스와 저산소증이 발병 기전에 관여 할 수 있다고 알려진다. 또한, vancomycin은 신장 근위 세뇨관으로 분비되며 그렇기 때문에 이를 vancomycin으로 유도 된 신 독성이 일어나는 장소로 가설을 세웠다. Vancomycin is an antibiotic isolated from Streptomyces orientalis, a glycopeptide antibiotic that has been used to treat methicillin-resistant staphylococcus aureus (MRSA) infection for more than 50 years. The bactericidal action appears quickly and the development of bacterial resistance is not remarkable. Since it is not absorbed from the digestive tract, it is administered intravenously and has a long duration of action. Side effects include skin rash and hypersensitivity reaction at the time of fever, but the main ones are auditory nerve disorder and kidney disorder. The reported incidence of vancomycin-induced nephrotoxicity ranges from 5 to 25%. Although the exact mechanism of vancomycin-induced nephrotoxicity is unknown, it is known that oxidative stress and hypoxia may be involved in the pathogenesis. In addition, vancomycin is secreted into the renal proximal tubule, so it is hypothesized that this is the site of vancomycin-induced nephrotoxicity.

본 연구의 목적은 Vancomycin에 의해 유도 된 급성신부전, 신장 손상 및 산화스트레스에 대한 고소애와 해마 혼합 추출물의 보호 효과를 확인하는 것이다.The purpose of this study was to investigate the protective effects of a mixture of extracts of height love and hippocampus against acute renal failure, renal injury and oxidative stress induced by vancomycin.

실시예 1Example 1

고소애high love 해마 혼합 추출물 제조 Preparation of hippocampus mixed extract

고소애 및 해마 주정 혼합물을 추출한 방법은 건조되어 분쇄기로 분쇄한 고소애분말 500 g과 해마 분말 500g에 70% 발효 에탄올을 10배수 넣고, 상온에서 24시간 침지 하여 추출하였다. 추출 후에 체로 한번 거른 후, 추출물을 여과지 (whatman No.1)를 이용하여 여과처리 하였다. 감압농축 (ratary evaporator N-1200, Eyela, Japan)을 하여 에탄올을 제거하고 최종 부피가 1L가 되도록 한 후 시료로 사용하였다. 이 때 최종 농도는 0.5 g/ml이다.The method of extracting the mixture of high love and hippocampus spirits was extracted by immersing 500 g of dried and crushed hippocampus powder and 500 g of hippocampus powder in 10 folds of 70% fermented ethanol at room temperature for 24 hours. After sifting through a sieve once after extraction, the extract was filtered using filter paper (whatman No. 1). Ethanol was removed by concentration under reduced pressure (ratary evaporator N-1200, Eyela, Japan), and the final volume was 1L, which was then used as a sample. At this time, the final concentration is 0.5 g/ml.

실시예 2Example 2

실험동물 및 시료투여Experimental animals and sample administration

26마리 male Sprague Dawley rat (5주령, 약 180-200 g)를 1주일 동안 순화 한 후 랜덤으로 다음과 같이 군을 나누어 투여하였다. 대조군 (n=8); 2주일 동안 증류수를 경구투여 하고, 마지막 3일 동안 saline을 복강내 주사하였다. Vancomycin 투여군(n=9); 2주일 동안 증류수를 경구투여 하고, 마지막 3일 동안 400 mg/kg의 vancomycin을 5 ml/kg으로 하루에 한번 복강 내 주사하였다. 고소애 해마 혼합 주정추출물+vancomycin투여군 (n=9)은 2주일 동안 고소애 해마 혼합 주정추출물을 10 ml/kg으로 경구투여하고, 마지막 3일 동안 vancomycin을 투여물질 투여 1시간 후 복강내 주사하였다. 사육환경은 12 h light/dark cycle, 22 ± 2 ℃ 온도, 50 ± 10% 습도를 유지시켰다. 모든 동물에 commercial food (Purina Inc., Gyeonggi-Do, Korea)와 물을 자유롭게 공급하였다. 모든 동물은 일주일에 두 번 체중 측정을 하였고, 마지막 투여 24시간 후 희생되었고 희생 전 12시간 동안 물을 제외하고 모든 음식을 절식하였다. 구체적인 시료투여 조건은 하기의 표 1과 같다. Twenty-six male Sprague Dawley rats (5 weeks old, about 180-200 g) were acclimatized for one week, and then randomly divided into groups as follows. control (n=8); Distilled water was orally administered for 2 weeks, and saline was injected intraperitoneally for the last 3 days. vancomycin-treated group (n=9); Distilled water was orally administered for 2 weeks, and 400 mg/kg of vancomycin was injected intraperitoneally once a day at 5 ml/kg for the last 3 days. The hippocampus mixed alcohol extract + vancomycin administration group (n=9) was orally administered 10 ml/kg of the hippocampus mixed alcohol extract, and for the last 3 days, vancomycin was intraperitoneally injected 1 hour after administration of the administered substance. . The breeding environment was maintained at 12 h light/dark cycle, 22 ± 2 ℃ temperature, and 50 ± 10% humidity. Commercial food (Purina Inc., Gyeonggi-Do, Korea) and water were supplied ad libitum to all animals. All animals were weighed twice a week, sacrificed 24 hours after the last administration, and fasted from all food except water for 12 hours before sacrifice. Specific sample administration conditions are shown in Table 1 below.

표1Table 1

Figure pat00001
Figure pat00001

Figure pat00002
Figure pat00002

실시예 3Example 3

고소애high love 해마 혼합 추출물 투여에 의한 신장무게의 이상 소견 여부 검증 Verification of abnormal findings in kidney weight by administration of hippocampus mixed extract

급성 신독성 동물모델에서의 반코마이신 처리 후 신장 조직의 무게변화 측정 결과를 도 1에 나타내었다. 급성신증 대조군(반코마이신 군)의 신장무게는 1.9 g으로 정상군의 신장 무게와 비교하여 58.3%의 증가를 보였으나, 고소애 해마 혼합 추출물 군에서는 1.7 g으로 신독성 대조군의 89.5% 수준인 것을 확인할 수 있었다. 1 shows the results of measuring the weight change of kidney tissue after vancomycin treatment in an animal model of acute nephrotoxicity. The kidney weight of the acute nephropathy control group (vancomycin group) was 1.9 g, an increase of 58.3% compared to that of the normal group. could

도1.Figure 1.

Figure pat00003
Figure pat00003

실시예 4Example 4

고소애high love 해마 혼합 hippocampus mixed 추출물추출물에in the extract extract 의한 신장기능의 이상 소견 여부 검증 Verification of abnormal findings of renal function by

신장 독성을 평가하기 위해, 상기 실시예 1에서 제조된 고소애 해마 혼합 추출물의 반코마이신에 의한 신장독성에 대한 개선효과를 하기와 같이 혈중 BUN(Blood Urea Nitrogen)과 creatinine의 수치를 측정하여 확인하였다. In order to evaluate renal toxicity, the improvement effect of the hippocampus mixed extract prepared in Example 1 on renal toxicity by vancomycin was confirmed by measuring blood urea nitrogen (BUN) and creatinine levels as follows.

가) 실험방법A) Test method

최종 희생일에 모든 실험동물을 12시간 이상 절식 후 배대동맥으로부터 혈액을 채취하며, 상온에서 1시간 정도 방치한 다음 3,000 rpm으로 원심분리하여 혈청을 분리하였다. 이후 On the final sacrifice day, all experimental animals were fasted for 12 hours or more, blood was collected from the abdominal aorta, left at room temperature for about 1 hour, and then centrifuged at 3,000 rpm to separate serum. after

혈중 BUN과 creatinine 함량은 commercial kit를 이용하여 각각 측정하였다. Blood BUN and creatinine contents were measured using a commercial kit, respectively.

나) 실험결과B) Experiment results

급성 신부전 동물모델에서는 반코마이신 처리 후 혈중 BUN과 creatinine 측정 결과를 도 2에 나타내었다. 반코마이신을 투여하면 혈중 BUN 농도가 35 mg/dL로 약 2.9배 증가죄는 것을 확인하였고, 고소애 해마 혼합 추출물 투여시 BUN의 수치는 반코마이신으로 유도된 BUN의 수치와 비교하여 77.1% 정도로 유의 있게 억제됨을 확인 할 수 있었다. In the acute renal failure animal model, the blood BUN and creatinine measurement results after vancomycin treatment are shown in FIG. 2 . It was confirmed that the administration of vancomycin increased the blood BUN concentration by about 2.9 times to 35 mg/dL, and the BUN level was significantly suppressed by 77.1% compared to the vancomycin-induced BUN level when the hippocampus mixed extract was administered. was able to confirm

정상군과 비교하여 급성 신부전 대조군인 vancomycin에서의 혈중 creatinine 수치는 0.54 mg/dL로 약 2.4배의 증가가 관찰 되었으나 고소애 해마 혼합 추출물 투여군에서는 약간의 감소 효과를 나타내었다. Compared to the normal group, the serum creatinine level in the acute renal failure control group, vancomycin, was 0.54 mg/dL, a 2.4-fold increase was observed.

도2.Figure 2.

Figure pat00004
Figure pat00004

Figure pat00005
Figure pat00005

실시예 5Example 5

고소애high love 해마 혼합 추출물 투여에 의한 신장조직의 형태학적 이상 소견 여부 검증 Verification of morphological abnormality of kidney tissue by administration of hippocampus mixed extract

신장조직의 형태학적 변화를 평가하기 위해, 신장조직의 Hematoxylin-Eosin (H&E) 염색과 신장 피질의 기저막을 보기 위한 Periodic acid-Schiff(PAS) 염색을 실시한 후 관찰하였다. To evaluate the morphological changes in renal tissue, Hematoxylin-Eosin (H&E) staining of renal tissue and Periodic acid-Schiff (PAS) staining were performed to see the basement membrane of renal cortex.

가) 실험방법A) Test method

최종 희생일에 시험동물에서 적출한 왼쪽 신장은 10% 중성 포르말린으로 고정시켜 알코올 탈수, 자일렌, 파라핀 침투 과정을 거쳐 section하였고, 후에 Hematoxylin-Eosin (H&E) 염색을 하여 조직을 관찰 후 광학현미경으로 관찰하였다. Periodic acid-Schiff(PAS) 염색은 0.5% periodic acid로 산화시킨 후, Schiff시약으로 발색시켰고, 핵염색은 Harris hematoxylin으로 한 후 조직을 관찰 후 광학 현미경으로 관찰하였다. On the final day of sacrifice, the left kidney excised from the test animal was fixed in 10% neutral formalin and sectioned through alcohol dehydration, xylene, and paraffin infiltration, followed by Hematoxylin-Eosin (H&E) staining, tissue observation, and optical microscopy. Observed. Periodic acid-Schiff (PAS) staining was oxidized with 0.5% periodic acid, followed by color development with Schiff reagent, and nuclear staining was performed with Harris hematoxylin, followed by tissue observation and observation under an optical microscope.

나) 실험결과B) Experiment results

신장의 형태학적 변화를 평가하기 위해 수치를 표준화하여 진행하였다. 신장의 형태학적 변화 평가 항목으로는 tubular dilation, tubular cell desquamation, tubular vacuolation, interstitial inflammation, interstitial edema, cast이 있고, 이를 다음과 같이 측정하여 평균화하였다. In order to evaluate the morphological changes of the kidney, the values were normalized and proceeded. The evaluation items for morphological changes in the kidney include tubular dilation, tubular cell desquamation, tubular vacuolation, interstitial inflammation, interstitial edema, and cast, which were measured and averaged as follows.

grade 0 : normalgrade 0 : normal

grade 1 : focal, mild grade 1: focal, mild

grade 2 : moderategrade 2: moderate

grade 3 : severe grade 3: severe

도 3에 나타난 바와 같이, 급성 신부전 동물모델의 신장에서는 정상군과 비교하여 반코마이신 군에서는 tubular dilation, cell desquamation, vacuolation, interstitial inflammation, interstitial edema, cast 형성을 확인하였다. 이것은 세뇨관 상피 괴사 및 탈락을 포함한 국소 변성을 특징으로 하는 전형적인 급성신부전증 경우의 소견이 인정되었다. 그러나 고소애 해마 혼합 추출물 투여군에서는 이러한 변화가 개선되는 것이 관찰되었다. 표 2는 도3의 결과를 바탕으로 조직병리학 급성 신독성을 수치화하여 정량화하여 나타낸 결과이다. As shown in FIG. 3, tubular dilation, cell desquamation, vacuolation, interstitial inflammation, interstitial edema, and cast formation were confirmed in the vancomycin group compared to the normal group in the kidney of the acute renal failure animal model. This was recognized as a typical case of acute renal failure characterized by focal degeneration including tubular epithelial necrosis and desquamation. However, it was observed that these changes were improved in the group administered with the mixed extract of the algae hippocampus. Table 2 is a result of quantifying and quantifying histopathological acute renal toxicity based on the results of FIG. 3.

도3.Figure 3.

Figure pat00006
3
Figure pat00006
3

표2.Table 2.

Figure pat00007
Figure pat00007

도 4의 결과는 신장 조직의 PAS 염색 결과를 나타낸 것이다. 조직학적 변화를 관찰한 결과 정상군에서는 기저막과 근위 세뇨관의 brush border에 선명하고 진한 PAS 양성 반응을 보인다. 반면 반코마이신군에서는 기저막의 PAS 양성 반응이 약해지고, 근위 세뇨관의 brush border가 소실되어 줄어든 PAS 양성 반응을 보였다. 고소애 해마 혼합 추출물을 투여한 군에서는 반코마이신 군 보다 근위 세뇨관의 brush border 소실이 덜 일어난 것으로 관찰되었다. The results of FIG. 4 show the results of PAS staining of kidney tissue. As a result of observing histological changes, the normal group showed a clear and dark PAS-positive reaction on the brush border of the basement membrane and proximal tubule. On the other hand, in the vancomycin group, the PAS-positive reaction of the basement membrane was weakened and the brush border of the proximal tubule was lost, resulting in a reduced PAS-positive reaction. The brush border loss of the proximal tubule was observed to be less in the group administered with the ALA hippocampus mixed extract than in the vancomycin group.

도4.Figure 4.

Figure pat00008
Figure pat00008

실시예 6Example 6

고소애high love 해마 혼합 추출물 투여에 의한 신장 조직의 염증 및 Inflammation of kidney tissue by administration of hippocampus mixed extract and 근위세뇨관의proximal tubular 손상 개선 검증 Damage remediation verification

가) 실험방법A) Test method

신장피질의 염증을 관찰하기 위해 Tumor necrosis factor alpha(TNF-α) 면역염색을 진행하였다. 항원성 부활을 위해 0.1 % trypsin으로 37℃, 30분 incubation하였고, 내인성효소활성억제를 위해 3 % H2O2 in methanol로 실온에서 30분 incubation하였고, 비특이적 반응 차단을 위해 3% bovine serum albumin in 1.5 % normal goat serum in 1x PBS(pH 7.4)로 실온에서 1시간 incubation하였고, 1차항체로 TNF-α (1:200 in 3% bovine serum albumin in 1.5 % normal goat serum in 1x PBS(pH 7.4; ab66579, abcam)를 사용하여 4℃ overnight을 진행하였고, 2차항체는 biotinylated goat anti-rabbit IgG로 실온에서 30분 incubation하였고, 3,3-diaminobenzidine tetrahydrochloride로 visualization하였다. 대조염색으로 Harris hematoxylin을 사용하였다.Tumor necrosis factor alpha (TNF-α) immunostaining was performed to observe inflammation in the renal cortex. Incubation was performed at 37°C for 30 minutes with 0.1% trypsin for antigenic revitalization, incubation with 3% H2O2 in methanol for 30 minutes at room temperature to inhibit endogenous enzyme activity, and 3% bovine serum albumin in 1.5% normal to block non-specific reactions. Incubation was performed for 1 hour at room temperature with goat serum in 1x PBS (pH 7.4), and TNF-α (1:200 in 3% bovine serum albumin in 1.5% normal goat serum in 1x PBS (pH 7.4; ab66579, abcam) was used as the primary antibody. ) was used to proceed overnight at 4 ° C., the secondary antibody was incubated with biotinylated goat anti-rabbit IgG for 30 minutes at room temperature, and visualized with 3,3-diaminobenzidine tetrahydrochloride Harris hematoxylin was used for counterstaining.

신장의 proximal tubule의 손상을 관찰하기 위해 N-Acetyl-β-D-Glucosaminidase(NAG) 면역염색을 진행하였다. 항원성 부활을 위해 microwave를 사용하여 low power에서 10분동안 1x citrate buffer(pH6.4)와 함께 boiling한 후 microwave안에서 30분 동안 cooling을 하였고, 내인성효소활성억제를 위해 0.5 % H2O2inmethanol로 실온에서 30분 incubation하였고, 비특이적 반응 차단을 위해 3% bovine serum albumin in 1.5 % normal goat serum in 1x PBS(pH 7.4)로 실온에서 20분 동안incubation하였고, 1차항체로 NAGLU (1:2000 in 3% bovine serum albumin in 1.5 % normal goat serum in 1x PBS(pH 7.4); ab217671, abcam)를 사용하여 4℃, 30분동안 incubation하였으며, 2차항체는 biotinylated goat anti-rabbit IgG를 사용하여 실온에서 30분 incubation하였고, 3,3-diamino-N-Acetyl-β-D-Glucosaminidase (NAG) immunostaining was performed to observe damage to the proximal tubule of the kidney. After boiling with 1x citrate buffer (pH 6.4) for 10 minutes at low power using a microwave for antigenic revival, it was cooled for 30 minutes in a microwave, and 0.5% H2O2inmethanol at room temperature for 30 minutes to inhibit endogenous enzyme activity. Incubation was performed for 20 minutes at room temperature with 3% bovine serum albumin in 1.5% normal goat serum in 1x PBS (pH 7.4) to block non-specific reactions, and NAGLU (1:2000 in 3% bovine serum) as the primary antibody. Albumin in 1.5% normal goat serum in 1x PBS (pH 7.4); ab217671, abcam) was used for incubation at 4°C for 30 minutes, and secondary antibody was incubated for 30 minutes at room temperature using biotinylated goat anti-rabbit IgG. , 3,3-diamino-

benzidine tetrahydrochloride로 visualization하였다. 대조염색으로 Harris hematoxylin을 사용하였다.Visualized with benzidine tetrahydrochloride. Harris hematoxylin was used as a counterstain.

나) 실험결과B) Experiment results

도 5에 나타난 바와 같이, 정상군과 비교했을 때 반코마이신에 의한 급성 신부전 동물모델의 신장조직에서 TNF-α의 발현이 현저히 증가하였다. 반면에 고소애 해마 혼합 추출물 투여군에서는 TNF-α의 발현이 감소되는 것이 관찰되었다. 신장의 세뇨관에 존재하는 효수 중 하나인 NAG의 발현 여부를 확인함으로써 신장 세뇨관의 기능 손상을 확인한 실험 결과를 도 6에 나타내었다. 정상군보다 반코마이신에서 세뇨관 내 NAG의 발현이 증가된 반면에 고소애 해마 혼합 추출물 투여군에서는 NAG의 발현이 감소된 것이 관찰되었다. As shown in Figure 5, the expression of TNF-α in the kidney tissue of the acute renal failure animal model by vancomycin was significantly increased when compared to the normal group. On the other hand, it was observed that the expression of TNF-α was decreased in the group administered with the mixed extract of the algae hippocampus. Fig. 6 shows the experimental results of confirming functional damage of renal tubules by checking the expression of NAG, which is one of the enzymes present in renal tubules. It was observed that the expression of NAG in the renal tubule was increased in vancomycin compared to the normal group, whereas the expression of NAG was decreased in the group administered with the hippocampus mixed extract.

도5.Figure 5.

Figure pat00009
Figure pat00009

도6.Figure 6.

Figure pat00010
Figure pat00010

실시예 7 Example 7

고소애 해마 혼합 추출물 투여에 의한 신장 조직의 세포 사멸 개선 여부 검증 Verification of improvement in apoptosis of renal tissue by administration of mixed extract of alpine hippocampus

가) 실험방법A) Test method

신장피질에 있는 근위 세뇨관 세포의 세포 사멸을 보기 위해 Terminal deoxynucleotidyl transferase dUTP nick end labeling(TUNEL)을 진행하였다. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed to see apoptosis of proximal tubular cells in the renal cortex.

파라핀 섹션한 신장을 탈파라핀 과정을 거친 후, 항원성 부활을 위해 0.1% trypsin in 1x PBS(pH 7.4)로 37℃, 10분 incubation하였다. 내인성 효소억제를 위해 3% H2O2 in methanol로 실온에서 30분 incubation한 후 Enzyme solution과 label solution을 혼합하여 분주한 후 37℃에서 1시간 incubation하였고, convent POD를 넣고 37℃에서 30분 incubation하였다. 시각화하기 위해 기질로 3,3-diaminobenzidine tetrahydrochloride을 사용하였고 대조염색으로 Harris hematoxylin을 사용하였다. TUNEL positive cell counting을 하여 scoring을 진행하였다. 랜덤으로 400배로 5개 시야를 관찰하여 TUNEL positive cell을 counting하여 전체 핵의 개수를 백분율로 나타내었다. The paraffin-sectioned kidneys were deparaffinized, and then incubated with 0.1% trypsin in 1x PBS (pH 7.4) at 37°C for 10 minutes to revive antigenicity. To inhibit endogenous enzymes, after incubation with 3% H2O2 in methanol at room temperature for 30 minutes, enzyme solution and label solution were mixed and dispensed, incubated at 37 ° C for 1 hour, and convent POD was added and incubated at 37 ° C for 30 minutes. For visualization, 3,3-diaminobenzidine tetrahydrochloride was used as a substrate and Harris hematoxylin was used as a counterstain. Scoring was performed by TUNEL positive cell counting. Five fields of view were randomly observed at 400 times magnification and TUNEL positive cells were counted, and the total number of nuclei was expressed as a percentage.

나) 실험결과B) Experiment results

도 7에 나타난 바와 같이, TUNEL 양성 세포는 원위세뇨관 핵에 보였고, 정상군과 비교했을 때 반코마이신 처리 군에서 TUNEL 양성 세포의 수가 증가한 것을 확인하였다. 반면에 고소애 해마 혼합 추출물 투여군에서는 TUNEL 양성 세포의 수가 감소 된 것을 관찰하였다. 도 8의 그래프는 도 7에 나타난 결과를 토대로 TUNEL 양성 세포의 수를 세어 백분율로 나타낸 것이다. As shown in FIG. 7 , TUNEL-positive cells were seen in the distal tubular nucleus, and it was confirmed that the number of TUNEL-positive cells increased in the vancomycin-treated group compared to the normal group. On the other hand, it was observed that the number of TUNEL-positive cells was decreased in the group administered with the mixed extract of the algae hippocampus. The graph of FIG. 8 shows the number of TUNEL-positive cells counted based on the results shown in FIG. 7 and expressed as a percentage.

도7.Figure 7.

Figure pat00011
Figure pat00011

도8.Figure 8.

Figure pat00012
Figure pat00012

실시예 8Example 8

고소애 해마 혼합 추출물 투여에 의한 신장 조직의 Malondialdehyde(MDA) 수치 변화 검증Verification of Malondialdehyde (MDA) level change in renal tissue by administration of mixed extracts of heightened hippocampus

가) 실험방법A) Test method

지질 과산화 정도를 측정하기 위해 MDA kit (sta-330, Cell Biolabs,INC.)를 사용하여 진행하였다. 조직의 MDA를 측정하기 위해 100 mg/ ml in 1x PBS(pH 7.4)로 조직을 homogenization하여 4℃, 10,000 g, 5분 centrifuge하여 600 ul supernant에 6 ul 100x BHT를 첨가하였다. 추후 분석을 위해 -80℃ 보관하였다. MDA standard 와 sample에 100 ul SDS lysis solution을 첨가하였고, thoroughly mix한 후 room temperature에서 5분동안 incubation 한 후 standard와 sample에 250 ul Thiobarbituric acid(TBA) reagent를 첨가 한 후 95℃, 60분동안 air dry oven에서 incubation하였다. ice위에서 실온으로 5분간 cooling한 후 3000rpm, 15분동안 sample을 centrifuge하였다. Hemoglobin과 hemoglobin의 derivatives의 interference를 막기위해 300 ul의 상층액을 다른 Eppendorf tube에 넣고 300 ul n-buthanol을 첨가한 후 vigorously vortex를 1분 동안 한 후 10,000 g, 5분 centrifuge하였다. 96 well plate에 standard와 sample의 상층액을 200 ul씩 넣고 532 nm에서 흡광도를 측정하였다.To measure the degree of lipid peroxidation, MDA kit (sta-330, Cell Biolabs, INC.) was used. To measure the MDA of the tissue, the tissue was homogenized with 100 mg/ml in 1x PBS (pH 7.4), centrifuged at 4°C, 10,000 g, and 5 minutes, and 6 ul 100x BHT was added to 600 ul supernant. Stored at -80°C for later analysis. 100 ul SDS lysis solution was added to the MDA standard and sample, and after thoroughly mixing, incubation was performed at room temperature for 5 minutes, and then 250 ul Thiobarbituric acid (TBA) reagent was added to the standard and sample, followed by air at 95℃ for 60 minutes. Incubation was performed in a dry oven. After cooling to room temperature on ice for 5 minutes, the samples were centrifuged at 3000 rpm for 15 minutes. To prevent interference between hemoglobin and hemoglobin derivatives, 300 ul of the supernatant was put into another Eppendorf tube, 300 ul of n-buthanol was added, vigorously vortexed for 1 minute, and centrifuged at 10,000 g for 5 minutes. 200 ul each of the supernatant of the standard and sample was placed in a 96 well plate, and the absorbance was measured at 532 nm.

나) 실험결과B) Experiment results

MDA는 지방 과산화시에 만들어지는 대사물로 산화적 스트레스의 지표로 이용되고 있다. 신장 조직을 수집해 MDA 수치를 측정해 본 결과를 도 9에 나타내었다. 정상군과 비교해보면, MDA 수치가 반코마이신 투여 군에서 증가하였다. 고소애 해마 혼합 추출물을 투여한 군에서는 반코마이신 단독 처리 군에 비해 MDA 수치가 감소하는 것을 확인하였다. MDA is a metabolite produced during fat peroxidation and is used as an indicator of oxidative stress. The results of measuring the MDA level by collecting kidney tissue are shown in FIG. 9 . Compared with the normal group, the MDA level increased in the vancomycin-treated group. In the group administered with the hippocampus mixed extract, it was confirmed that the MDA level decreased compared to the group treated with vancomycin alone.

도9.Figure 9.

Figure pat00013
Figure pat00013

본 발명은 고소애와 해마 혼합 추출물이 혈중 요소 질소(BUN) 함량, 혈중 크레아티닌(Cr) 함량, 괴사 세뇨관 세포수를 감소시키고, 산화 스트레스를 방어함으로써 신장 기능을 증진시킴을 확인하였다. 따라서 본 발명은 신장질환의 예방 및 치료 용도를 갖는 약학 조성물 및 신장 기능을 개선시키는 건강기능식품으로 유용하게 이용될 수 있다. In the present invention, it was confirmed that the mixed extract of P. aphid and hippocampus reduced blood urea nitrogen (BUN) content, blood creatinine (Cr) content, and the number of necrotic tubular cells, and improved kidney function by defending against oxidative stress. Therefore, the present invention can be usefully used as a pharmaceutical composition having a use for preventing and treating kidney disease and a health functional food for improving kidney function.

은 Vancomycin에 의해 유도 된 급성신부전, 신장 손상 및 산화스트레스에 대한 고소애와 해마 혼합 추출물의 보호 효과를 확인하는 것이다.was to confirm the protective effect of a mixture of extracts of height love and hippocampus against acute renal failure, renal damage and oxidative stress induced by vancomycin.

Claims


KR1020170164875A 2017-12-04 2017-12-04 Pharmaceutical composition for preventing and treating kidney disease use extract containing mealworm and hippocampus abdominalis, health functional food composition KR102445881B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020170164875A KR102445881B1 (en) 2017-12-04 2017-12-04 Pharmaceutical composition for preventing and treating kidney disease use extract containing mealworm and hippocampus abdominalis, health functional food composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170164875A KR102445881B1 (en) 2017-12-04 2017-12-04 Pharmaceutical composition for preventing and treating kidney disease use extract containing mealworm and hippocampus abdominalis, health functional food composition

Publications (2)

Publication Number Publication Date
KR20190065581A true KR20190065581A (en) 2019-06-12
KR102445881B1 KR102445881B1 (en) 2022-09-21

Family

ID=66845931

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020170164875A KR102445881B1 (en) 2017-12-04 2017-12-04 Pharmaceutical composition for preventing and treating kidney disease use extract containing mealworm and hippocampus abdominalis, health functional food composition

Country Status (1)

Country Link
KR (1) KR102445881B1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1011335A (en) * 1911-04-17 1911-12-12 Joseph D Flaig Tie.
US1762167A (en) * 1927-08-15 1930-06-10 Premier Cushion Spring Company Helical coiler and assembler
KR101011333B1 (en) 2005-01-31 2011-01-28 동화약품주식회사 Pharmaceutical composition for treating nephropathy and healthy food comprising herb extracts
KR101762167B1 (en) 2015-12-08 2017-07-27 김정천 pharmaceutical composition for preventing and treating kidney disease use gallic extract, health functional food composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1011335A (en) * 1911-04-17 1911-12-12 Joseph D Flaig Tie.
US1762167A (en) * 1927-08-15 1930-06-10 Premier Cushion Spring Company Helical coiler and assembler
KR101011333B1 (en) 2005-01-31 2011-01-28 동화약품주식회사 Pharmaceutical composition for treating nephropathy and healthy food comprising herb extracts
KR101762167B1 (en) 2015-12-08 2017-07-27 김정천 pharmaceutical composition for preventing and treating kidney disease use gallic extract, health functional food composition

Also Published As

Publication number Publication date
KR102445881B1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
Abd El-Hack et al. Pharmacological, nutritional and antimicrobial uses of Moringa oleifera Lam. leaves in poultry nutrition: an updated knowledge
KR101107034B1 (en) Feed additives for cultivated fish consisting herbal mixture water extracts of sophorae flavescens aition, citrus unshiu markovich, lonicera japonica thunberg, benincasa hispida cogniaux, perilla frutescens var. acuta kudo and scutellaria baicalensis georgi as an active ingredient and feed for cultivated fish therewith
Stegelmeier et al. Selected poisonous plants affecting animal and human health
CN105146180A (en) Hairy crab compound feed
Ben Hadda et al. Effect of garlic and cabbage on healing of gastric ulcer in experimental rats
KR100920713B1 (en) A composition for the treatment or prevention of diarrhea
Nan et al. An ethanolic extract of Allium hookeri root alleviates reflux esophagitis and modulates NF-κB signaling
KR102445881B1 (en) Pharmaceutical composition for preventing and treating kidney disease use extract containing mealworm and hippocampus abdominalis, health functional food composition
KR20150051597A (en) Food Composition for improving liver function containing extract of Arctiumlappa L.
KR101544783B1 (en) A composition comprising an extract of combined crude drugs for treating and preventing Male Infertility
KR20190065647A (en) A pharmaceutical composition and health functional food for preventing and treating kidney disease comprising Hippocampus abdominalis extract
Mondal et al. Acalypha indica–a boon to mankind
Mulyani et al. In vivo test of rhizophora mucronata mangrove extract from pangandaran coast towards Nile Tilapia Oreochromis niloticus infected by Vibrio harveyi
Anuforo et al. Terminalia catappa flour extract mitigated monosodium glutamate intoxicated rats’ kidney biofunction and histology
Ahmed et al. Observation on pediculosis in buffalo-cows with emphasis on its impact on ovarian activity and control by herbal remedies
Kianifard Protective effects of Morus Alba (M. Alba) extract on the alteration of testicular tissue and spermatogenesis in adult rats treated with Monosodium Glutamate
Gürbüz et al. Does eugenol have potential as an anti-campylobacter and antioxidant compound in the food industry and clinical settings?
Atama et al. Psychotria microphylla induces oxidative stress and biochemical alterations in giant African land snail Achatina achatina (Linnaeus, 1758)
Mitra et al. Plants used as ethnoveterinary medicine in Uttar and Dakshin Dinajpur districts of West Bengal, India
Dandi INFLUENCE OF BITTER LEAF EXTRACT ON NILE TILAPIA GROWTH, HEMATOLOGY, AND HEAT STRESS RESPONSE
KR102251942B1 (en) The composition of immune enhancement for beekeeping
Morales-Covarrubias et al. Biopotentials of mangroves
Shanmugavel Antibacterial Activity of Mucuna Pruriens Seed Extract on Vibrio Harveyi Infected Litopenaeus Vannamei
Nayal Master of Veterinary Science
Kusi et al. Diets supplemented with phytobiotics C alopogonium mucunoides, Ocimum gratissimum, and Tridax procumbens improve growth, immunity, and Oreochromis niloticus resistance to Streptococcus agalactiae

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right